Search research articles
Contact Us
Filters
Showing results (181-190 of 319) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
The Oncologist
|
February 4, 2012
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
Philip J Saylor, Kevin R Kozak, Matthew R Smith, et al.
Cancer
|
October 7, 2004
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
Matthew R Smith, Judith Manola, Donald S Kaufman, et al.
Medical Physics
|
January 26, 2024
Spectral analysis of non-contrast fluoroscopy for evaluation of pulmonary perfusion: Feasibility and sensitivity testing with a phantom
Matthew R Smith, Jared V Grice, Dennis W Zhou, et al.
Journal of Medicinal Chemistry
|
May 19, 2015
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity
Michael B Tropak, Jianmin Zhang, Sayuri Yonekawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2009
A structured exercise program for patients with advanced non-small cell lung cancer
Jennifer S Temel, Joseph A Greer, Sarah Goldberg, et al.
Clinical Pharmacokinetics
|
September 11, 2014
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer
Kim Stuyckens, Fred Saad, Xu Steven Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2005
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
William K Oh, Elizabeth Hagmann, Judith Manola, et al.
Prostate Cancer and Prostatic Diseases
|
December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis
Fabio Turco, Silke Gillessen, Giorgio Treglia, et al.
The Journal of Urology
|
December 20, 2014
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer
Huei-Ting Tsai, Nancy L Keating, Stephen K Van Den Eeden, et al.
Page
of 32
Search research articles
Search
Showing results (181-190 of 319) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
The Oncologist
|
February 4, 2012
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
Philip J Saylor, Kevin R Kozak, Matthew R Smith, et al.
Cancer
|
October 7, 2004
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
Matthew R Smith, Judith Manola, Donald S Kaufman, et al.
Medical Physics
|
January 26, 2024
Spectral analysis of non-contrast fluoroscopy for evaluation of pulmonary perfusion: Feasibility and sensitivity testing with a phantom
Matthew R Smith, Jared V Grice, Dennis W Zhou, et al.
Journal of Medicinal Chemistry
|
May 19, 2015
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity
Michael B Tropak, Jianmin Zhang, Sayuri Yonekawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2009
A structured exercise program for patients with advanced non-small cell lung cancer
Jennifer S Temel, Joseph A Greer, Sarah Goldberg, et al.
Clinical Pharmacokinetics
|
September 11, 2014
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer
Kim Stuyckens, Fred Saad, Xu Steven Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2005
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
William K Oh, Elizabeth Hagmann, Judith Manola, et al.
Prostate Cancer and Prostatic Diseases
|
December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis
Fabio Turco, Silke Gillessen, Giorgio Treglia, et al.
The Journal of Urology
|
December 20, 2014
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer
Huei-Ting Tsai, Nancy L Keating, Stephen K Van Den Eeden, et al.
Page
of 32